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Abstract
Background: Wolfram syndrome is a rare disorder associated with diabetes mellitus, diabetes insipidus, optic nerve
atrophy, hearing and vision loss, and neurodegeneration. Sleep complaints are common but have not been studied
with objective measures. Our goal was to assess rates of sleep apnea and objective and self-reported measures of
sleep quality, and to determine the relationship of sleep pathology to other clinical variables in Wolfram syndrome
patients.
Methods: Genetically confirmed Wolfram syndrome patients were evaluated at the 2015 and 2016 Washington
University Wolfram Syndrome Research Clinics. Patients wore an actigraphy device and a type III ambulatory sleep
study device and completed the Epworth Sleepiness Scale (ESS), the Pittsburgh Sleep Quality Index (PSQI) and/or
the Pediatric Sleep Questionnaire (PSQ). PSQI and PSQ questionnaire data were compared to a previously collected
group of controls. Patients were characterized clinically with the Wolfram Unified Rating Scale (WURS) and a subset
underwent magnetic resonance imaging (MRI) for brain volume measurements.
Results: Twenty-one patients were evaluated ranging from age 8.9–29.7 years. Five of 17 (29%) adult patients fit the
criteria for obstructive sleep apnea (OSA; apnea-hypopnea index [AHI] ≥ 5) and all 4 of 4 (100%) children aged 12
years or younger fit the criteria for obstructive sleep apnea (AHI’s ≥ 1). Higher AHI was related to greater disease
severity (higher WURS Physical scores). Higher mixed apnea scores were related to lower brainstem and cerebellar
volumes. Patients’ scores on the PSQ were higher than those of controls, indicating greater severity of childhood
obstructive sleep-related breathing disorders.
Conclusions: Wolfram syndrome patients had a high rate of OSA. Further study would be needed to assess how
these symptoms change over time. Addressing sleep disorders in Wolfram syndrome patients would likely improve
their overall health and quality of life.
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Background
Wolfram syndrome is a rare autosomal recessive dis-
order that is caused by mutations in the WFS1 or,
less commonly, the WFS2 gene [1, 2]. WFS1 encodes
an endoplasmic reticulum protein wolframin [1],
which is thought to play a role in protection against
ER stress-related apoptosis [3]. The clinical manifesta-
tions of Wolfram syndrome can include childhood
onset of diabetes mellitus, diabetes insipidus, optic
nerve atrophy, hearing and vision loss, motor impair-
ment, and neurodegeneration [4].
Clinically defined classic Wolfram syndrome has been
associated with a limited lifespan, and causes of death
may have included central or obstructive sleep apnea. In
a case series of 45 patients with the classic manifesta-
tions of diabetes insipidus, diabetes mellitus, optic atro-
phy, and deafness (DIDMOAD), the median age of
death was 30 years (range 25–49 years) and central re-
spiratory failure with brainstem atrophy was noted as a
cause [5]. In another series of 68 patients also defined by
the clinical manifestations of DIDMOAD, more than
50% of the 23 patients who died had symptoms of sig-
nificant neurodegeneration, including apneic spells [6].
Now that genetic identification of Wolfram syndrome is
possible, it is apparent that the clinical phenotype is
broader than previously described [7]. Thus, the natural
history of respiratory issues and their severity across the
continuum of the disease phenotype is unclear.
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Understanding the nature of sleep dysfunction in
Wolfram syndrome has implications for the health
and potentially the longevity of patients. Sleep com-
plaints are common in Wolfram syndrome patients
and are associated with their overall quality of life,
but have not been well-characterized by sleep studies
or actigraphy [8]. The presence or severity of sleep
dysfunction could be related to the known regional
neuropathology of Wolfram syndrome. Wolfram syn-
drome is associated with decreased brainstem (especially
the ventral pons) and cerebellar volumes, among other re-
gions, compared to controls [9, 10]. These regions also
have been shown to be involved in or affected by sleep
apnea in humans [11, 12].
The present study was designed to objectively measure
sleep quality and assess the presence of obstructive and
central sleep apnea in genetically confirmed Wolfram
syndrome patients. In addition, we explored whether
disease severity and neuropathology as measured by re-
gional brain volumes relate to sleep dysfunction. Study-
ing sleep may provide more information on the natural
history of Wolfram syndrome, help us understand any
sleep-related health risks including those possibly con-
tributing to mortality, and perhaps identify important
targets for intervention.
Methods
Patients and study design
Wolfram syndrome patients were recruited through the
Washington University Wolfram Syndrome Research
Clinic, an annual event to collect data relevant to the
natural history of the disease, ongoing since its inception
in 2010. Patients were recruited through physician refer-
ral and the Washington University Wolfram Syndrome
International Registry. For enrollment in the research
clinic, patients had to be age 30 years or younger at
entry, have genetically confirmed Wolfram syndrome
(mutations of the WFS1 gene) and be willing and able to
travel to St. Louis. Individuals with Wolfram syndrome
completed a comprehensive series of evaluations and
questionnaires across multiple domains (sleep, vision,
hearing, urology, cognition, psychiatry, neurology, bal-
ance and gait, taste and smell, endocrinology and mag-
netic resonance imaging [MRI]) during the research
clinic. Analyses from subsets of these data have been
reported elsewhere [7–10, 13–21].
This paper focuses on sleep data from Wolfram pa-
tients in relation to other disease severity and brain
volume variables and compares self-reported sleep
problems to a previously reported sleep questionnaire
dataset from controls. Wolfram patient data reported
here were collected from all willing Wolfram clinic
participants from 2015 and 2016. These were the
clinic years that ambulatory sleep study devices and
personnel were made available from the Washington
University Sleep Medicine Center. No additional
exclusion criteria were applied for sleep assessment
participants. Controls were composed of individuals
with type 1 diabetes (T1DM) and non-diabetic
healthy controls who were recruited through the
Pediatric Diabetes Clinic at St. Louis Children’s
Hospital and through word-of-mouth [8, 9].
Sleep assessments
Ambulatory sleep study
Wolfram syndrome patients slept in a hotel affiliated
with Washington University during their clinic participa-
tion and agreed to wear an ambulatory sleep device on
one of the nights. Patients in the 2015 clinic wore an
ApneaLink™ type III ambulatory sleep study device
(ResMed Corporation, Poway, Calif ). Patients in the
2016 clinic wore a Phillips Respironics Alice NightOne
type III ambulatory sleep study device (Koninklijke
Philips N.V.). The ambulatory sleep study devices were
placed on patients during evening hours and removed
during morning hours by registered sleep technologists
(RST) employed by the Washington University Sleep
Medicine Center. Data collection was considered ad-
equate if four or more interpretable hours of data were
obtained [22]. The ambulatory sleep studies were re-
peated once within the same clinic year if the initial
night of recording showed insufficient data collection or
if there were technical issues.
The ambulatory sleep studies were scored initially by a
RST and all data was also scored and interpreted by a
board-certified sleep physician (AL; American Board of
Psychiatry and Neurology with Added Qualification in
Sleep Medicine). Sleep studies were scored according to
standards established by the American Academy of Sleep
Medicine (AASM) Manual for the Scoring of Sleep and
Associated Events: Rules, Terminology and Technical
Specification version 2.3, including the scoring of
obstructive apneas, obstructive hypopneas, and central
apneas [23]. The apnea hypopnea index (AHI), obstruct-
ive apnea index (OAI), central apnea index (CAI),
hypopnea index (HI), mixed apneas index (MAI), and
oxygen desaturation index (ODI) were calculated for
each ambulatory sleep study based on recording time.
Adult scoring criteria was used if the patient was 13
years of age or older. Pediatric scoring criteria was used
if the patient was 12 years of age or younger per practice
guidelines outlined in the International Classification of
Sleep Disorders, 3rd edition [24].
Criteria for the diagnosis of obstructive sleep apnea
(OSA) and central sleep apnea (CSA) followed the
International Classification of Sleep Disorders (ICSD),
3rd edition. OSA was defined per ICSD criteria as
“five or more predominantly obstructive respiratory
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events (obstructive and mixed apneas, hypopneas, or
respiratory effort related arousals [RERAs]) per hour
of sleep” noted during a sleep study for adult pa-
tients, and per ICSD criteria as “one or more ob-
structive apneas, mixed apneas, or hypopneas, per
hour of sleep” for pediatric patients [24]. Adults with
an overall AHI of greater than or equal to 5 events
per hour of sleep were classified as having OSA if
there was a predominance of obstructive respiratory
events, and children with an obstructive AHI of
greater than or equal to 1 event per hour of sleep
were classified as having OSA [24]. CSA was defined
per ICSD criteria as CAI of greater than or equal to
5 events per hour [24].
The AHI has been considered the primary metric for
diagnosis of OSA based on clinical and research prece-
dence [25, 26]. The AHI has been determined to be a re-
liable indicator of OSA severity and also of morbidity
and mortality related to OSA, including risk of all-cause
mortality, cardiovascular disease, arrhythmias, and inci-
dent stroke [25, 26]. Therefore, the AHI was the primary
sleep variable chosen for further analyses as described
below.
Actigraphy
Wolfram syndrome patients wore a Phillips Respironics
Actiwatch 2, a type of activity monitor that is similar to
a wristwatch and is sensitive to motor activity (Bend,
OR). Patients wore the Actiwatches for one night. Acti-
graphy data was analyzed, including the tracings and the
numerical data, noting in particular the following pa-
rameters: mean sleep efficiency, mean sleep latency, and
mean sleep duration. These parameters were chosen to
characterize sleep quality and quantity.
Sleep questionnaires
The Epworth Sleepiness Scale (ESS) [27] and Pittsburgh
Sleep Quality Index (PSQI) [28] and the Pediatric Sleep
Questionnaire (PSQ) [29] were administered via a web-
based data collection tool (REDCap) within a few
months prior to the patients’ arrival at the clinic [30].
The ESS is designed to assess degree of sleepiness, with
questions asking the likelihood of falling asleep in eight
different conditions rated on a four-point Likert-type
scale (0 = never, 3 = high chance) (range of scores 0–24,
> 10 is considered abnormal) [27]. The PSQI is designed
to assess sleep disturbances, with questions asking the
extent to which various factors interfered with sleep on
a four-point Likert-type scale (0 = not at all, 3 = three or
more times a week), with subscales of subjective sleep
quality, sleep latency, sleep duration, habitual sleep effi-
ciency, sleep disturbances, use of sleeping medication,
and daytime dysfunction (range of scores 0–21, > 5 is
considered abnormal) [28]. The PSQ assesses symptoms
of childhood obstructive sleep-related breathing disor-
ders (SRBDs) and includes snoring, sleepiness, and be-
havior subscales (range of scores 0–1, > 0.33 is
considered abnormal) [29]. For the Wolfram group, par-
ents completed the PSQI and the PSQ on their children
younger than age 18 years. If the Wolfram patient was
18 years or older, he/she completed the PSQI. For the
control group, parents completed the PSQ for their chil-
dren younger than age 18 years, and control participants
18 years or older completed the PSQI. Matching ques-
tionnaires were compared across groups.
Disease severity variables
Wolfram unified rating scale (WURS) – physical
A neurologist administered the WURS [8, 19], a vali-
dated instrument developed to measure disease severity
of Wolfram syndrome sequelae (e.g. vision, hearing,
motor, urological, neurological, psychological and mood
problems) and has been shown to have good inter-rater
reliability and validity [19]. We used the physical sub-
scale (maximum score = 160) as our measure of neuro-
logic severity [19].
The physical and neurological examination for subtle signs
(PANESS)
A trained examiner administered the PANESS, an age-
normalized motor dysfunction assessment tool [31, 32].
Visual acuity
Best-corrected visual acuity was measured by Snellen
optotype by a pediatric optometrist. The data were
transformed into the logMAR scale for analyses [15].
Regional brain volumes
As part of the overall natural history study, eligible pa-
tients performed MRI scans on a Siemens 3 Tesla Tim
Trio at Washington University. Multiple anatomical se-
quences were obtained. Analyses here used data only
from the T1-weighted Magnetization-Prepared Rapid
Gradient-Echo (MPRAGE) sequence (sagittal acquisi-
tion, repetition time (TR) = 2400, echo time (TE) = 3.16,
inversion time (TI) = 1000, voxel resolution = 1 × 1 × 1
mm, Time = 8:09 min). Regional brain volumes were ex-
tracted using Freesurfer 5.3, averaged between right and
left hemispheres as appropriate and corrected for esti-
mated total intracranial volume. The brainstem was then
manually segmented into its major components: mid-
brain, basilar (ventral) pons, tegmentum (dorsal pons),
and medulla, as previously described [9]. Brain volumes
chosen for analyses were pons (ventral, dorsal, and
total), medulla, and cerebellum (gray and white matter)
due to their involvement in Wolfram syndrome or OSA
[9, 10, 33], and association with respiration [34].
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Statistical analysis
Nonparametric statistics were used due to the small sam-
ple sizes and the non-normality of many of the sleep vari-
ables and the ranked nature of the WURS scoring. Group
comparisons were performed with Mann-Whitney U tests,
and correlations were performed with Spearman’s r. All
statistical analyses were conducted in IBM SPSS©
Version 25 (Armonk, NY).
To determine if the Wolfram group had more sleep-
related problems than controls, we compared PSQ and
PSQI scores across groups. To assess whether Wolfram
patients with reported sleep problems were more likely
to have apneas, we compared the AHI values of the
subset of those with abnormal scores on the PSQ or
PSQI to those with normal scores. In addition, we corre-
lated AHI with sleep efficiency, sleep latency, sleep time,
PSQI, PSQ and ESS total scores.
To assess whether Wolfram neurologic severity was
related to rates of abnormal events during monitoring,
we correlated AHI to WURS total score, PANESS total
score and visual acuity, and to regional brain volumes
known to be affected in Wolfram syndrome and in-
volved in sleep (ventral and total pons, medulla, cerebel-
lar gray and cerebellar white matter). Finally, we
explored whether any of the other sleep study indices
(CAI, MAI, OAI, and HI) correlated with these brain
regions. To evaluate whether any confounding variables
in Wolfram syndrome patients could explain sleep prob-
lems, we correlated AHI with age, diabetes duration,
hemoglobin A1c (HbA1c; to assess recent glycemic




Twenty-eight patients received sleep assessments
(ambulatory sleep studies and/or actigraphy) in 2015
and 33 patients received sleep assessments (ambulatory
sleep studies and/or actigraphy) in 2016.Twenty-seven
patients obtained sleep assessments in both clinic years.
Twenty-eight patients wore the ApneaLink ambulatory
sleep monitoring device in 2015, 12 patients wore the
Respironics Night One ambulatory sleep monitoring
device in 2016, and 8 patients wore both devices. In total,
32 unique patients had one or more sleep studies.
Twenty-one patients had at least 4 h of interpretable sleep
study data on at least one attempt (11 from 2015 and 10
from 2016). Eleven patients’ sleep studies were not
included in the analyses due to poor data quality. Four
studies were scored using pediatric scoring criteria and 17
studies were scored using adult scoring criteria. Reasons
for declining ambulatory sleep study testing included a
prior clinical diagnosis of obstructive sleep apnea treated
with continuous positive airway pressure (CPAP) nightly
(n = 1), lack of availability of the ambulatory sleep moni-
toring device (n = 2), and anticipated discomfort with the
testing (n = 4). Clinical sleep study records were requested
for all patients and obtained and reviewed in two cases.
Both patients had been diagnosed with moderate obstruct-
ive sleep apnea by in-lab sleep studies.
There were 33 individual patients who wore the
Actiwatch during the 2015 and 2016 clinics, including
27 patients who wore the Actiwatch in both 2015 and
2016. Actiwatch data was selected for analyses from
2015 or 2016 to match the year that the subject had
valid sleep study data, except in two cases in which
Actiwatch data quality was poor during the year that
sleep study data was collected.
Twenty-one patients completed both ambulatory sleep
study testing and Actiwatch data collection. Of these 21
patients, mean sleep efficiency was 84% (SD = 11.6,
range = 36.9–93.2), mean sleep onset latency was 35.7
min (SD = 72.6, range = 3.0–346.5), and mean sleep dur-
ation was 441.7 min (SD = 90.5, range = 220.0–624.5).
71% of the patients who completed both ambulatory
sleep study testing and Actiwatch data collection were
female. See Table 1 for further demographic and clinical
information.
Brain MRI data was available on 15/21 of the Wolfram
syndrome patients with good quality ambulatory sleep
studies. This subgroup had a mean age of 18.1 years
(SD = 5.9, range = 8.9–29.7 years) and was 60% female.
Controls
One control’s PSQ total score was an outlier (> 3 S.D.
above the mean) and was therefore excluded from the
primary analysis. The control group (n = 22) with
PSQ scores was comprised of T1DM (n = 11) and
healthy control (n = 11) individuals (mean age = 13.8
years [S.D. = 2.9], age range 8.6–17.8 years; 50%
female). The outlier had T1DM, was 14 years old, and
male. The control group (n = 10) with PSQI scores
was comprised of T1DM (n = 4) and healthy control
(n = 6) individuals (mean age = 19.6 years [S.D. = 1.6],
age range 18.1–23.1 years; 70% female).
Sleep study data (Table 2, Table 1)
The mean overall AHI was 5.6, with a range of 0–22.
Five of 17 (29%) adult patients had overall AHI’s greater
than or equal to 5 with a predominance of obstructive
respiratory events, indicating obstructive sleep apnea.
All 4 of 4 children aged 12 years or younger had overall
AHI’s greater than or equal to 1 and obstructive AHI’s
greater than or equal to 1, indicating obstructive sleep
apnea in 100% of the pediatric Wolfram syndrome
sample population.
One adult patient had a CAI of greater than or equal
to 5 events per hour (CAI = 17/h, overall AHI = 22). A
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previous clinical in-lab sleep study on this patient found
that this patient had moderate obstructive sleep apnea,
with central apneas in the normal range. Thus, this
outlier was removed from all further analyses of AHI
due to this discrepancy.
Sleep questionnaire results (Table 1, Fig. 1)
On the PSQ, 5/15 (33%) parents of Wolfram patients
and 0/22 (0%) parents of controls reported symptoms of
sleep-disordered breathing (score of > 0.3). When the
control outlier (PSQ score = 0.6) was included, 1/23
(0.04%) parents reported symptoms of sleep-disordered
breathing. On the PSQI, 6/18 (33%) Wolfram patients
and 2/10 (20%) controls reported disturbed sleep (score
of > 5). Wolfram patients (mean = 0.19, [S.D. = 0.16],
range = 0–0.41) had higher PSQ scores than controls
(mean = 0.06 [S.D. = 0.07], range = 0–0.23; Mann-
Whitney U, p = 0.02; mean ± SD for Wolfram patients
Table 1 Clinical, sleep, and brain volume data in Wolfram syndrome patients
Mean SD Minimum Maximum N
Age (years) 18.0 5.8 8.9 29.7 21
Diabetes Duration (years) 12.4 6.3 0.0 26.5 21
BMI 23.2 5.0 16.1 33.0 20
HbA1c (%) 7.9 1.9 5.0 12.4 19
Apnea Hypopnea Index (AHI) 5.6 5.3 0.0 22.0 21
Sleep Efficiency (%)a 84.0 11.6 36.9 93.2 21
Sleep Onset Latency (minutes)a 35.7 72.6 3.0 346.5 21
Total sleep time (minutes)a 441.7 90.5 220.0 624.5 21
PSQI Total Score 5.7 3.3 1.0 12.0 18
PSQ Total Score 0.19 0.16 0 0.41 15
ESS Total Score 6.4 3.7 2.0 15.0 17
WURS Physical Score 11.1 9.7 1.0 35.0 21
PANESS Total Score 37.3 15.8 11.0 71.0 18
Visual Acuity (Logmar) 0.7 0.5 0.0 1.9 20
Ventral Pons Volume (mm3) 5933.9 1311.7 4316.6 7830.3 15
Dorsal Pons Volume (mm3) 2941.5 292.9 2563.6 3494.3 15
Total Pons Volume (mm3) 8875.4 1457.9 6997.6 10918.4 15
Medulla Volume (mm3) 2045.2 190.4 1751.0 2449.3 15
Cerebellar White Matter Volume (mm3) 11363.2 1651.9 8000.2 14355.3 15
Cerebellar Gray Matter Volume (mm3) 45064.8 4188.2 37680.2 55467.4 15
SD standard deviation, BMI body mass index, HbA1c Hemoglobin A1c, PSQI Pittsburgh Sleep Quality Index, PSQ Pediatric Sleep Questionnaire, ESS Epworth
Sleepiness Scale, WURS Wolfram Unified Rating Scale, PANESS Physical and Neurological Examination for Subtle Signs. All data in Table 1 represents only Wolfram
patients, and does not include controls
adata collected from Actiwatch
Table 2 Descriptive statistics for sleep study indices in Wolfram syndrome patients
Index Mean
# normal / # abnormal
SD Minimum Maximum N
Overall Apnea-Hypopnea Index 5.6
children: 0 / 4
adults: 12 / 5
5.3 0 22 21
Obstructive Apnea-Hypopnea Index 3.4 3.2 0.4 10.7 21
Obstructive Apnea Index 0.2 0.7 0 3 21
Central Apnea Index 2.0 3.6 0 17 21
Mixed Apnea Index 0.2 0.3 0 1 21
Hypopnea Index 3.2 3.0 0 10.6 21
Oxygen Desaturation Index 3.5 4.5 0 15.8 21
SD Standard deviation
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and controls are shown in Fig. 1, data for Wolfram
patients shown in Table 1). When the control outlier
was included, Wolfram patients still had higher PSQ
scores than controls (mean = 0.08 [S.D. = 0.13];
Mann-Whitney U, p = 0.05; data not shown). PSQI
scores were not significantly different between Wol-
fram patients (Table 1) (mean = 5.7 [S.D. = 3.3],
range = 1.0–12.0) and controls (mean = 4.1 [S.D. =
2.7], range = 0–10) (Mann-Whitney U, p = 0.22).
Overall AHI did not differ between Wolfram patients
with and without abnormal PSQ scores (for abnormal
PSQ mean AHI = 5.1, S.D. = 1.6; for normal PSQ mean
AHI = 4.9, S.D. = 3.6; p = 0.95), or PSQI scores (for abnor-
mal PSQI mean AHI = 7.6, S.D. = 4.6; for normal PSQI
mean AHI = 4.0, S.D. = 2.7; p = 0.10). On the ESS, 3/17
Wolfram patients had abnormal sleepiness (18%; score >
10).
Correlations
Overall AHI correlated with the WURS Physical Score such
that patients with greater neurological severity tended to
have higher AHI scores (rs = 0.51, p = 0.023; Fig. 2). AHI
did not correlate with visual acuity (rs = 0.15, p = 0.54) or
PANESS score (rs = − 0.03, p = 0.90), with regional brain
volumes (p > 0.13), sleep questionnaires (p > 0.29), actigra-
phy measures (sleep efficiency, mean sleep latency, or
sleep duration; p > 0.36), or primary clinical measure
(age, diabetes duration, HbA1c, and BMI; p > 0.65).
There were 4 Wolfram patients that did not have
T1DM. Only one had an ambulatory sleep study,
which did not reveal OSA. In exploratory analyses of
other sleep indices and brain regions, we found that
the MAI negatively correlated with ventral pons (rs =
− 0.63, p = 0.015), total pons (rs = − 0.60, p = 0.02),
and cerebellar white matter (rs = − 0.55, p = 0.04)
volumes, such that those with more respiratory events
tended to have lower volumes in these regions (Fig. 3a-c).
CAI positively correlated with cerebellar gray matter vol-
ume (rs = 0.62, p = 0.018, Fig. 3d), such that a higher cen-
tral apnea index was associated with higher volume.
Although these correlations are intriguing, and, for the
CAI/cerebellar gray matter association, difficult to inter-
pret, it is important to note that none of them would sur-
vive multiple comparison correction.
Discussion
Wolfram syndrome is a complex disorder involving
neurodevelopmental, metabolic, urinary, sensory, and
other symptoms, many of which could interfere with
sleep. This paper provides quantified objective assessment
of sleep dysfunction in Wolfram syndrome, a fundamental
area of investigation not reported previously. Wolfram
syndrome patients in our sample had a high rate of sleep-
disordered breathing, particularly OSA. Both adults and
children with Wolfram syndrome had much higher rates
of OSA than the general population (e.g. 29.4% vs. 2–7%
[35] for adults and 100% vs. 1–5% for children [36]). An
unexpected finding was that OSA was present early in the
disease course. We found that all 4 of our pediatric pa-
tients met the criteria for OSA, with the youngest being
only 8.9 years old. Our questionnaire results support these
findings, since symptoms of OSA were endorsed by par-
ents of children with Wolfram syndrome at higher rates
than in control children. However, our pediatric sample
size is too small to provide a prevalence assessment. Also,
this study was underpowered for a reliable comparison of
frequency of symptoms of OSA in control adults versus
adult Wolfram patients. The high rate of OSA in the Wol-
fram syndrome population is a novel finding and may pro-
vide a clinical target for improving health and quality of
life in Wolfram syndrome patients.
Fig. 1 Symptoms of sleep-disordered breathing, as assessed by the
Pediatric Sleep Questionnaire (PSQ). Scores are shown from Wolfram
syndrome patients (solid circles) and age-matched control individuals
(open circles). More symptoms of sleep-disordered breathing were
reported in Wolfram syndrome patients compared to age-matched
control individuals. Mean ± SD shown. *p < 0.05 compared to controls
Fig. 2 Correlation between Apnea Hypopnea Index (AHI) and
Wolfram Unified Rating Scale (WURS) Physical scores. AHI was
positively correlated with WURS Physical scores (rS = 0.51, p = 0.02)
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AHI was associated with overall disease severity as
measured by a neurologist-administered clinical rating
scale (WURS Physical), which is suggestive of a disease-
related process underlying the presence and severity of
AHI. AHI was not associated with duration of insulin
dependent diabetes, glycemic control, or BMI in our
sample. However, adults with type 1 diabetes (T1DM)
have been shown to have a relatively high prevalence of
OSA, even among non-obese adults [37]. In a meta-ana-
lysis of 22 studies, the estimated prevalence of
obstructive sleep apnea (OSA) in adults with T1DM was
51.9% (95% CI = 31.2, 72.6), and mean BMI was between
22.9 and 25.8 kg/m [37], similar to our sample of WFS
patients. Sleep disturbance has also been related to poor
glycemic control [38]. Finally, autonomic neuropathy, as
seen in diabetes, may affect control of pharyngeal mus-
cles, contributing to increased risk of obstructive sleep
apnea [39, 40]. We cannot rule out the hypothesis that
insulin dependent diabetes or its complications affect
sleep in Wolfram syndrome, but we did not find any
relationship between diabetes duration or glycemic con-
trol and sleep disorders in our data. Thus, our present
data suggest neurologic factors may be more significant.
Larger samples would be needed to distinguish any addi-
tive or interactive effects between diabetes and neuro-
logic factors in influencing sleep dysfunction in Wolfram
syndrome. Due to our small sample size, we were not
able to assess prevalence of OSA in Wolfram syndrome
in the absence of diabetes.
Our interest in the relationships between neuropathol-
ogy and sleep disturbance in Wolfram syndrome pa-
tients was driven by a number of factors. First, sleep-
disordered breathing has been related to brainstem path-
ology in other disorders [41]. Second, sleep dysfunction
can have a negative impact on the brain. Neuroimaging
studies on patients with OSA have found decreased
blood flow and altered white matter in cerebellum and
brainstem regions [11, 12]. These regions are important
in cardiovascular control and coordination of the upper
airway musculature with the diaphragm [11, 42]. Third,
other neurodegenerative conditions have been associated
with sleep issues, which sometimes manifest among the
presenting symptoms of the disease [43]. Sleep disrup-
tion itself also may contribute to disease progression in
neurodegenerative conditions [43, 44]. Finally, Wolfram
syndrome patients may be particularly vulnerable to the
effects of sleep disruption at a cellular level, since the
endoplasmic reticulum (ER) protein wolframin [1] is
thought to play a role in protection against ER stress-re-
lated apoptosis [3]. Sleep disruption activates ER stress
[45, 46], and in turn, ER stress in Drosophila has been
associated with sleep fragmentation and alteration of
recovery sleep, indicating a bidirectional relationship
between ER stress and sleep [47]. Thus, it is possible
Fig. 3 Correlations between brain volumes and sleep apnea index scores in Wolfram syndrome patients. Mixed apnea index (MAI) scores
were negatively correlated with (a) ventral pons (rS = − 0.63, p = 0.015), b total pons (rS = − 0.60, p = 0.02, and (c) cerebellar white matter
volumes (rS = − 0.55, p = 0.04). d Central apnea index (CAI) scores were positively correlated with cerebellar gray matter volume (rS = 0.62,
p = 0.02). No p-value survived multiple comparisons correction
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that the neuropathophysiologic aspects of Wolfram syn-
drome cause or are influenced by sleep disordered
breathing. Because of this background, we had hypothe-
sized that reduced regional brain volumes in Wolfram
syndrome may be related to sleep disordered breathing.
While we found that higher MAI was associated with
lower volumes in ventral pons, total pons, and cerebellar
white matter volumes, we also found that higher CAI
was correlated with greater cerebellar gray matter vol-
ume. These are intriguing findings which would need to
be explored in a larger sample.
Strengths of this study include the detailed
characterization of this cohort, the novel nature of this
investigation, and the use of multiple instruments to as-
sess sleep, including the interpretation of ambulatory
sleep studies by a board-certified sleep specialist, actigra-
phy data, questionnaires, and correlations with clinical
variables and brain volume data. Limitations include the
small sample size. However, for a rare disorder studied
with quantitative methods, the sample size is relatively
large. Ambulatory sleep studies were obtained rather
than in-lab sleep studies because of feasibility issues with
obtaining the latter. Certain respiratory events, such as
respiratory effort-related arousals and hypopneas associ-
ated with arousals from sleep, cannot be scored on
ambulatory sleep studies because arousals based on elec-
troencephalography (EEG) criteria cannot be identified
[24]. Also, ambulatory sleep studies may underestimate
the frequency of respiratory events since actual sleep
time, as determined by EEG data, is not available on
most ambulatory sleep studies [24]. Another limitation
is that different brands of ambulatory sleep studies were
used in the 2 clinic years of the study, due to a change
in the available brand carried by the Washington
University sleep center. There are missing data involving
many of the parameters studied. Brain MRI data was not
available on the entirety of the cohort receiving sleep
assessments. However, basic demographic data did not
differ significantly between those with and without brain
MRI data. Ambulatory sleep study devices, actigraphy,
and personnel were accessible for only a limited time-
frame. Finally, data were gathered during the Wolfram
research clinic during which most patients were sleeping
in a hotel after traveling, which could bias our results.
However, we found that sleep efficiency and sleep dur-
ation in our cohort were comparable to values found
among healthy subjects, but sleep onset latency was
higher in our cohort [48, 49]. In addition, self and parent
reports suggest that Wolfram syndrome patients have
greater sleep disturbances in their home setting com-
pared to controls.
Future directions could include longitudinal examin-
ation of sleep issues in Wolfram syndrome and applica-
tion of sleep-center based polysomnograms to provide
relatively more reliable prevalence estimates of OSA in
Wolfram syndrome than the ambulatory sleep study-
based estimates available through this study. A larger
sample size would facilitate additional exploration of the
relationships among sleep issues, neuroimaging findings,
and other clinical characteristics in Wolfram syndrome
and could help clarify whether variations in sleep pheno-
types are associated with variations in genetic mutations.
The natural history of OSA in Wolfram syndrome is un-
clear due to the fact that our data are cross-sectional. In
many neurodegenerative disorders, sleep issues are one
of the heralding symptoms of disease onset [43]. Further
study is required to assess whether sleep issues often
arise early in the Wolfram syndrome disease course or
may even sometimes present before other Wolfram
syndrome symptoms manifest. Additionally, expanding
the patient population beyond the age of 30 years would
provide clarity on the evolution of sleep issues later in
the course of Wolfram syndrome. These data in turn
could help elucidate the relationship, if any, between
sleep disorders and mortality in Wolfram syndrome.
Conclusions
We have demonstrated that OSA is highly prevalent in
Wolfram syndrome and that higher AHI was related to
greater disease severity (higher WURS Physical scores).
We have suggested that there may be neuroanatomical
correlates with sleep disorders in Wolfram syndrome,
since higher mixed apnea scores were related to lower
brainstem and cerebellar volumes. Addressing sleep
disorders in Wolfram syndrome patients and improving
their sleep quality may potentially alter the natural
history of the disease by mitigating ER stress and slow-
ing cell death. An understanding of the clinical course of
the sleep disorders may better clarify any co-segregation
of sleep disorders with other features of Wolfram
syndrome. As treatments for Wolfram syndrome are
developed, their effects on sleep issues should be stud-
ied. Sleep disorders likely have considerable effects on
the health and quality of life of Wolfram syndrome
patients and require further attention.
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